Form 4 for BIIB Biogen
Accepted 2022-04-05 00:00:00 ET · period of report 2022-04-01 · accession 0001127602-22-011610 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-04-05 | 2022-04-01 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | — | +239 | 1,897 | +14% | — |
| D | 2022-04-05 | 2022-04-01 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | F - Tax | $210.65 | -84 | 1,813 | -4% | -$17.7K |
| D | 2022-04-05 | 2022-04-01 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | — | -239 | 479 | -33% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-01 | M | A | 239 | — | 1,896.89 | D | — | — | (F1) Each restricted stock unit is converted to one share of common stock upon vesting. |
| 2 | Common | Common Stock | 2022-04-01 | F | D | 84 | $210.65 | 1,812.89 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2022-04-01 | M | D | 239 | — | 479 | D | $0.00 · — to 2024-04-01 | 239 Common Stock | (F1) Each restricted stock unit is converted to one share of common stock upon vesting. (F2) This award was granted to the reporting person on April 1, 2021 and vested with respect to 239 shares on April 1, 2022. The remaining portion of the award vests in equal installments on each of the second and third anniversary of the grant date. |